{
  "thread": {
    "uuid": "ec3cca8ee9af34dcd5fb9efb4490c183db3f3eca",
    "url": "https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/aiassist/pzzd/2026-01-15/doc-inhhkffx3432353.shtml&vt=4",
    "site_full": "cj.sina.cn",
    "site": "sina.cn",
    "site_section": "https://finance.sina.cn/?from=redirect",
    "site_categories": [
      "top_news_hk",
      "top_news_my",
      "top_news_sg",
      "top_news_tw",
      "top_news",
      "politics",
      "science and technology",
      "economy, business and finance"
    ],
    "section_title": "新浪财经_金融信息服务商",
    "site_title": "财经头条_新浪财经_金融信息服务商",
    "title": "华海药业跌2.05%，成交额3.57亿元，主力资金净流出3942.51万元",
    "title_full": "华海药业跌2.05%，成交额3.57亿元，主力资金净流出3942.51万元",
    "published": "2026-01-15T07:38:00.000+02:00",
    "replies_count": 0,
    "participants_count": 0,
    "site_type": "news",
    "country": "CN",
    "main_image": "https://n.sinaimg.cn/finance/c30320b4/20210712/wx_poster_finance1.png",
    "performance_score": 0,
    "domain_rank": 4801,
    "domain_rank_updated": "2026-01-11T23:00:00.000+02:00",
    "licensing_agency": [],
    "social": {
      "facebook": {
        "likes": 0,
        "comments": 0,
        "shares": 0
      },
      "vk": {
        "shares": 0
      }
    }
  },
  "uuid": "ec3cca8ee9af34dcd5fb9efb4490c183db3f3eca",
  "url": "https://cj.sina.cn/article/norm_detail?url=https://finance.sina.com.cn/stock/aiassist/pzzd/2026-01-15/doc-inhhkffx3432353.shtml&vt=4",
  "ord_in_thread": 0,
  "author": null,
  "published": "2026-01-15T07:38:00.000+02:00",
  "title": "华海药业跌2.05%，成交额3.57亿元，主力资金净流出3942.51万元",
  "text": "1月15日， 华海药业 盘中下跌2.05%，截至13:38，报17.19元/股，成交3.57亿元，换手率1.37%，总市值257.38亿元。\n资金流向方面，主力资金净流出3942.51万元，特大单买入1149.35万元，占比3.22%，卖出2991.39万元，占比8.38%；大单买入6352.53万元，占比17.80%，卖出8452.99万元，占比23.68%。\n华海药业今年以来股价涨1.30%，近5个交易日跌4.92%，近20日涨1.72%，近60日跌10.28%。\n资料显示， 浙江华海药业股份有限公司 位于浙江省台州市临海市汛桥镇汛大路88号，成立日期2001年2月28日，上市日期2003年3月4日，公司主营业务涉及多剂型的仿 制药 、生物药、创新药及特色原料药的研发、生产和销售。主营业务收入构成为：成品药销售61.86%，原料药及中间体销售36.75%，其他0.78%，技术服务0.62%。\n华海药业所属申万行业为： 医药生物 -化学制药-化学制剂。所属概念板块包括：仿制药、AI应用（医药医疗）、 生物医药 、原料药、创新药等。\n截至9月30日，华海药业股东户数6.84万，较上期增加1.58%；人均流通股21889股，较上期增加1.23%。2025年1月-9月，华海药业实现营业收入64.09亿元，同比减少11.57%；归母净利润3.80亿元，同比减少63.12%。\n分红 方面，华海药业A股上市后累计派现29.89亿元。近三年，累计派现10.16亿元。\n机构持仓方面，截止2025年9月30日，华海药业十大流通股东中， 中欧医疗健康混合A （003095）位居第三大流通股东，持股2878.50万股，相比上期减少446.18万股。香港中央结算有限公司位居第四大流通股东，持股2124.62万股，相比上期增加234.87万股。 富国优化增强债券C （100037）位居第六大流通股东，持股1343.23万股，为新进股东。南方中证500ETF（510500）位居第八大流通股东，持股1316.75万股，相比上期减少25.01万股。兴全趋势投资混合(LOF)（163402）位居第十大流通股东，持股1238.13万股，为新进股东。\n打开App看更多精彩内容",
  "highlightText": "",
  "highlightTitle": "",
  "highlightThreadTitle": "",
  "language": "chinese",
  "sentiment": "negative",
  "categories": [
    "Economy, Business and Finance"
  ],
  "topics": [
    "Economy, Business and Finance->business reporting and performance",
    "Economy, Business and Finance->market and exchange"
  ],
  "ai_allow": true,
  "has_canonical": false,
  "breaking": true,
  "webz_reporter": false,
  "external_links": [],
  "external_images": [],
  "internal_images": [],
  "entities": {
    "persons": [],
    "locations": [],
    "organizations": []
  },
  "syndication": {
    "syndicated": null,
    "syndicate_id": null,
    "first_syndicated": false
  },
  "trust": {
    "categories": [],
    "top_news": [
      "top_news_hk",
      "top_news_my",
      "top_news_sg",
      "top_news_tw",
      "top_news"
    ],
    "bias": null,
    "source": {
      "type": null,
      "city": null,
      "state": null,
      "country": null,
      "domain_type": null,
      "agency": null,
      "organization_name": null
    }
  },
  "rating": null,
  "crawled": "2026-01-15T07:46:48.639+02:00",
  "updated": "2026-01-15T07:47:15.000+02:00"
}